FIELD: medicine.
SUBSTANCE: group of inventions relates to medicine, namely to the use of milk or dairy products with increased content of beta-casein option that does not lead to the formation of beta-casomorphin-7 (hereinafter – BCM-7), when cleaved in the intestine of the specified human, to improve the cognitive function and to prevent cognitive disorders in a healthy human. The beta-casein option that does not lead to the formation of BCM-7, when cleaved in the human intestine, is a beta-casein option, in which proline is present in the position 67 in an amino acid sequence.
EFFECT: group of inventions provides for the reduction in the content of beta-casein A1 in the diet, which allows for the elimination of unfavorable effect of beta-casomorphin-7 (BCM-7) on cognitive functions.
11 cl, 5 dwg, 4 tbl, 2 ex
| Title | Year | Author | Number |
|---|---|---|---|
| BETA-CASEINS AND INTESTINAL MICROBIOTA | 2016 |
|
RU2769989C2 |
| A2 BETA-CASEIN AND REDUCTION OR PREVENTION OF SYMPTOMS OF LACTOSE INTOLERANCE | 2014 |
|
RU2791693C2 |
| BETA-CASEIN A2 AND REDUCING OR PREVENTING SYMPTOMS OF LACTOSE INTOLERANCE | 2014 |
|
RU2671562C2 |
| BETA-CASEIN A2 AND PREVENTION OF INTESTINAL INFLAMMATION | 2014 |
|
RU2784851C2 |
| BETA-CASEIN A2 AND PREVENTION OF INFLAMMATION OF INTESTINE | 2014 |
|
RU2669553C2 |
| BETA-CASEIN A2 AND BLOOD GLUCOSE LEVEL | 2014 |
|
RU2802806C1 |
| BETA-CASEIN A2 AND BLOOD GLUCOSE LEVEL | 2014 |
|
RU2698794C2 |
| BETA-CASEIN A2 AND ANTIOXIDANT CAPACITY | 2016 |
|
RU2751945C2 |
| SET OF SEQUENCES OF PRIMERS AND ALLELE-SPECIFIC PROBES FOR SIMULTANEOUS GENODIAGNOSIS OF FOUR MUTANT ALLELES OF BETA-CASEIN IN CATTLE | 2022 |
|
RU2798281C1 |
| METHOD FOR SIMULTANEOUS GENE DIAGNOSIS OF FOUR ALLELES OF BETA-CASEIN IN CATTLE AND TEST SYSTEM FOR ITS IMPLEMENTATION | 2022 |
|
RU2815238C2 |
